{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nonoxynol-9
to a specific field?
Status:
Investigational
Source:
NCT01371799: Phase 1 Interventional Completed Mental Disorders
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00612508: Not Applicable Interventional Completed Contraceptive Usage
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Dofamium is the antiseptic agent. It was used for the water sterilization.
Status:
Investigational
Source:
NCT00785408: Phase 2 Interventional Completed Obesity
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Davalintide (AC-2307) is a second-generation mimetic of a pancreatic peptide hormone amylin, developed by Amylin Pharmaceuticals. In preclinical models, davalintide possessed enhanced pharmacological properties and was able to reduce food intake. Safety, tolerability, and effect on body weight of subcutaneous davalintide were investigated in obese or overweight subjects. The results of the clinical trial were not reported, but Amylin decided to discontinue davalintide in 2010.
Status:
Investigational
Source:
NCT01705483: Phase 1 Interventional Terminated Pharmacokinetics of ASP9853
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00004026: Phase 2 Interventional Terminated Prostate Cancer
(1998)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
CT-2584 is a cytotoxic agent which modulates intracellular metabolism of phosphatidic acid in tumor cells. CT-2884 inhibits CTP:choline-phosphate cytidylyltransferase and causes de novo phospholipid biosynthesis via phosphatidic acid to be shunted away from phosphatidylcholine and into phosphatidylinositol. CT-2884 induced cytotoxicity is associated with disruption and swelling of endoplasmic reticulum and mitochondria. In the early 2000s, CT-2584 was investigated in phase 2 clinical trials for the treatment of prostate cancer and soft-tissue sarcoma. No development of the drug was reported since.
Status:
Investigational
Source:
NCT00003713: Phase 1 Interventional Completed Unspecified Adult Solid Tumor, Protocol Specific
(1997)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Intoplicine is a pyrido[4,3-b]indole derivative patented by Rhone-Poulenc Sante as an antitumor agent. Intoplicine acts via inhibiting DNA nicking and closing reactions by stabilizing the cleavable complex, a transient intermediate in the religation reaction involving topoisomerase I and II and DNA. Intoplicine was active in a range of solid tumors in mice, including colon adenocarcinoma 51, MA16/C, MA14/A, MA13/C, early-stage pancreatic ductal adenocarcinoma 03, Glasgow osteogenic sarcoma and B16 melanoma. In Phase I clinical studies using a 24-h infusion, the maximum tolerated dose was established as 270 mg/m2 every 3 weeks, with hepatotoxicity rather than myelosuppression being dose-limiting, although cardiac toxicity was also seen. Preclinical cytotoxic concentrations were not achieved at the dose levels studied and clinical development was discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Ricasetron (BRL 46470) is a selective serotonin 5-HT3 receptor antagonist. This compound was found to be a potent anxiolytic agent and have antiemetic (effective against vomiting and nausea) effects when tested in animal models. Moreover, this drug was reported to have less side effects than benzodiazepines (used for anxiety). Ricasetron was not further developed for medical use.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Ipazilide is an antiarrhythmic agent that prolongs ventricular refractoriness and possesses antiectopic activity. In clinical trials ipazilide administrations leads to dose- and time-dependent in decrease cardiac index and arterial pressure. Left ventricular filling pressure, right atrial pressure, and heart rate were not altered by ipazilide. Plasma concentrations of ipazilide peaked 90 minutes after administration of 100 or 200 of the drug, but peak concentrations were noted 3 hours after administration of 400 mg. The hemodynamic response correlated with the plasma concentration of ipazilide determined contemporaneously.
Status:
Investigational
Source:
NCT00044421: Phase 3 Interventional Completed Diabetic Neuropathies
(2002)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Ruboxistaurin is an orally bioavailable, selective, potent inhibitor of protein kinase C β developed for treating diabetic retinopathy. In vitro and in vivo non-clinical models have demonstrated that Ruboxistaurin decreases PKC β activity and ameliorates many of the effects of PKC β on pathologic processes in the retina. Ruboxistaurin prevents the slowing of retinal blood flow that is observed by fluorescein video angiography in the eyes of diabetic rats. It is also reported to cause regression of retinal neovascularization produced by laser-induced major branch vein occlusions in a porcine model. Ruboxistaurin positively affected the diabetes-induced retinal blood flow abnormalities in a Phase Ib study in diabetic patients. Ruboxistaurin is in phase III clinical trials for the treatment of diabetic nephropathy and diabetic macular edema. Eli Lilly had submitted Ruboxistaurin for approval in the US and the EU; however, the company subsequently discontinued development as it was unable to demonstrate sufficient efficacy
Status:
Investigational
Source:
NCT00606697: Phase 2 Interventional Completed Sleep Initiation and Maintenance Disorders
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Vofopitant (previously known as GR205171), a tetrazole-derivative, was developed as a neurokinin1 receptor antagonist. Vofopitant was studied in clinical trials phase II for the treatment of primary insomnia and posttraumatic stress disorder. However, these studies were discontinued due to lack of effectiveness. In addition, vofopitant participated in phase I for patients with bipolar disorder. However, this study was terminated because of the slow recruitment; trial unlikely to reach completion.
